All In Biotech

Drug Trial Radar · NCT07642843

CM336 for Active Sjogren's Syndrome Study

Evaluation of CM336 Injection for Active Sjogren's Syndrome: an Open-Label Phase Ib Study

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Apr 2028

Study completion Feb 2029

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Jun 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CM336 in adult participants with active primary Sjogren's Syndrome.

Conditions

  • Primary Sjögren's Syndrome (pSS)

Interventions

  • CM336Biological

    Participants will receive CM336 via subcutaneous injection in ascending dose cohorts

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: Throughout study (Up to 52 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.